Celularity Inc. Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent
Celularity Inc. (CELU) reported Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent of $5.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent · last filed 2026-04-30
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for the quarter ending 2025-12-31 was $0.00.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was $3.00K.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for the quarter ending 2025-06-30 was -$3.00K.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for the quarter ending 2025-03-31 was $5.00K.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for fiscal 2025 was $5.00K.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for fiscal 2024 was -$5.00K, a 103.42% decline from fiscal 2023.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for fiscal 2023 was $146.00K, a 630.00% increase from fiscal 2022.
- Celularity Inc. other comprehensive income (loss), financial liability, fair value option, before tax, after reclassification adjustment, attributable to parent for fiscal 2022 was $20.00K.
| Period end | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-04-30 | $3.00K derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | $5.00K 10-K · filed 2026-04-30 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $5.00K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2025-06-30 | -$3.00K 10-Q · filed 2025-11-14 | $2.00K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2025-03-31 | $5.00K 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | -$5.00K 10-K · filed 2026-04-30 | |||
| 2024-09-30 | -$2.00K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $146.00K 10-K · filed 2025-05-08 | |||
| 2023-06-30 | -$269.00K 10-Q · filed 2024-12-06 | $2.54M derived: sum of 2 quarters · filed 2024-12-06 | ||
| 2023-03-31 | $2.81M 10-Q · filed 2024-12-06 | |||
| 2022-12-31 | $20.00K 10-K · filed 2024-07-30 | |||
| 2022-09-30 | $236.00K 10-Q · filed 2024-01-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |